Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):1132–1135. doi: 10.1038/bjc.1993.208

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

U Ward 1, J N Primrose 1, P J Finan 1, T J Perren 1, P Selby 1, D A Purves 1, E H Cooper 1
PMCID: PMC1968452  PMID: 8494712

Abstract

Tumour markers CEA, CA-195 and CA-242 were measured in 33 patients undergoing chemotherapy for advanced colorectal cancer. The aim was to determine whether they could be used to accurately monitor the course of the disease, and reduce the need for imaging. Treatment with a 5-fluorouracil based regimen resulted in a partial response in nine patients (27%), whereas the remainder either had disease stabilisation or suffered from progression. Before treatment the CEA was elevated in 85% of patients and the CA-195 and CA-242 in 78%. All three markers were elevated in 70% and at least one elevated in 93%. CA-195 and CA-242 appeared to be co-expressed, by contrast with the CEA. When compared to the results of serial CT scanning the CEA correlated best with the course of the disease, the positive predictive value being 54% for a partial response, 77% for minor and partial responses combined and 100% for progressive disease. The corresponding values for CA-195 were 46%, 62% and 100% respectively and for CA-242, 50%, 67% and 100% respectively. Thus, although falling levels of markers overestimate the number of responses demonstrated by imaging, rising tumour markers invariably herald progressive disease. This was often evident up to 16 weeks before progression was observed on scanning. CEA is the most useful of the three markers in the monitoring of patients being treated for advanced colorectal cancer, but other markers may prove valuable if the CEA is normal. The use of tumour markers should reduce the need for regular scanning.

Full text

PDF
1132

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen-Mersh T. G., Kemeny N., Niedzwiecki D., Shurgot B., Daly J. M. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut. 1987 Dec;28(12):1625–1629. doi: 10.1136/gut.28.12.1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Minton J. P., Hoehn J. L., Gerber D. M., Horsley J. S., Connolly D. P., Salwan F., Fletcher W. S., Cruz A. B., Jr, Gatchell F. G., Oviedo M. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985 Mar 15;55(6):1284–1290. doi: 10.1002/1097-0142(19850315)55:6<1284::aid-cncr2820550622>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  3. Nilsson O., Johansson C., Glimelius B., Persson B., Nørgaard-Pedersen B., Andrén-Sandberg A., Lindholm L. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992 Feb;65(2):215–221. doi: 10.1038/bjc.1992.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Petrelli N., Douglass H. O., Jr, Herrera L., Russell D., Stablein D. M., Bruckner H. W., Mayer R. J., Schinella R., Green M. D., Muggia F. M. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989 Oct;7(10):1419–1426. doi: 10.1200/JCO.1989.7.10.1419. [DOI] [PubMed] [Google Scholar]
  5. Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. E., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989 Oct;7(10):1407–1418. doi: 10.1200/JCO.1989.7.10.1407. [DOI] [PubMed] [Google Scholar]
  6. Safi F., Bittner R., Roscher R., Kübel R., Beger H. G. The value of CA 19-9 in gastric and colorectal carcinoma. Cancer Invest. 1987;5(5):401–407. doi: 10.3109/07357908709032897. [DOI] [PubMed] [Google Scholar]
  7. Sagar P. M., Taylor O. M., Cooper E. H., Benson E. A., McMahon M. J., Finan P. J. The tumour marker CA 195 in colorectal and pancreatic cancer. Int J Biol Markers. 1991 Oct-Dec;6(4):241–246. doi: 10.1177/172460089100600405. [DOI] [PubMed] [Google Scholar]
  8. Staab H. J., Anderer F. A., Stumpf E., Hornung A., Fischer R., Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg. 1985 Feb;149(2):198–204. doi: 10.1016/s0002-9610(85)80064-7. [DOI] [PubMed] [Google Scholar]
  9. Wadler S., Schwartz E. L., Goldman M., Lyver A., Rader M., Zimmerman M., Itri L., Weinberg V., Wiernik P. H. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989 Dec;7(12):1769–1775. doi: 10.1200/JCO.1989.7.12.1769. [DOI] [PubMed] [Google Scholar]
  10. Wadler S., Wiernik P. H. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol. 1990 Feb;17(1 Suppl 1):16–41. [PubMed] [Google Scholar]
  11. Wanebo H. J., Llaneras M., Martin T., Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet. 1989 Dec;169(6):479–487. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES